cytidine monophosphate has been researched along with Cancer of Pancreas in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Blagden, SP; Kapacee, ZA; Knox, JJ; Lamarca, A; McNamara, MG; Palmer, D; Valle, JW | 1 |
| Bré, J; Chan, TH; Harrison, DJ; Mullen, P; Reynolds, PA; Sarr, A; Um, IH | 1 |
| Ashford, ML; Hales, CN; Reale, V | 1 |
1 review(s) available for cytidine monophosphate and Cancer of Pancreas
| Article | Year |
|---|---|
NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Clinical Trials as Topic; Cytidine Monophosphate; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Ovarian Neoplasms; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome | 2020 |
2 other study(ies) available for cytidine monophosphate and Cancer of Pancreas
| Article | Year |
|---|---|
Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Clinical Trials, Phase I as Topic; CRISPR-Cas Systems; Cytidine Monophosphate; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Female; Gemcitabine; HEK293 Cells; Humans; Ovarian Neoplasms; Pancreatic Neoplasms | 2019 |
Nucleotide Regulation of a calcium-activated cation channel in the rat insulinoma cell line, CRI-G1.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Animals; Calcium; Cell Line; Cytidine Monophosphate; Guanosine Monophosphate; Insulinoma; Ion Channels; Kinetics; Membrane Potentials; Pancreatic Neoplasms; Rats; Ribonucleotides; Structure-Activity Relationship; Tumor Cells, Cultured; Uridine Monophosphate | 1994 |